RIPK3,

Haixia Su1,2, Guofeng Chen3, Hang Xie4

  • 1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Shanghai, 201203, China. suhaixia1@simm.ac.cn.

PubMed
概括

新的RIPK3抑制剂在不诱导亡的情况下阻止了亡. 这些由特定突变启发的LK系列化合物表现出高激酶选择性,并以非活性形式稳定RIPK3以实现更安全的治疗开发.